Arca
Skip to content
Tools
Tools

MAP2K1, MAP2K2: Dual specificity mitogen-activated protein kinase kinase; MEK1/2

Family in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on MAP2K1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Other 1

Approved1

  • Trametinib

Phase 30

    Phase 20

      Phase 11

      • RG-7167

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      TrametinibApprovedNovartis PharmaceuticalsSmall moleculeInhibitorDual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor106
      RG-7167Phase 1—OtherInhibitorDual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      A Single-Arm,Multicenter Phase, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and AdolescentsTrametinibPhase 1 / Phase 2Enrolling by invitationSecond Affiliated Hospital of Wenzhou Medical UniversityOct 22, 2026
      Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid CancerTrametinibPhase 2Not yet recruitingWashington University School of MedicineOct 21, 2026
      A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral MelanomaTrametinibPhase 4Not yet recruitingPeking University Cancer Hospital & InstituteOct 2, 2026
      Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERITTrametinibPhase 3Not yet recruitingCarelon ResearchSep 14, 2026
      Molecularly Tailored Therapy in Advanced Pancreatic CancerTrametinibPhase 2Not yet recruitingHerlev HospitalSep 3, 2026
      A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) PatientsTrametinib—Not yet recruitingNovartis PharmaceuticalsAug 18, 2026
      A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular AnomaliesTrametinib—Not yet recruitingNovartis PharmaceuticalsAug 17, 2026
      24VA021; VATCH Trametinib for Ras/MAPK Pathway VAsTrametinibPhase 2RecruitingChildren's Hospital of PhiladelphiaApr 24, 2026

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2111289, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.